Experience with a luteinizing hormone-releasing hormone agonist in patients with prostate cancer

Abstract

Ключевые слова: гормональная терапия, рак предстательной железы, агонист лютеинизирующего гормона -рилизинг-гормон, лейпрорелин ацетат, тестостерон, ПСА, андрогенная блокада.The efficiency of hormone therapy was analyzed in patients with locally advanced or metastatic prostate cancer. Among all the drugs of a group of luteinizing hormone-releasing hormone agonists, leuprorelin acetate showed the best result in suppressing testosterone and PSA levels in urologic oncology practice. A clinical trial was done using different hormone treatment regimens, including orchiectomy, and different leuproprelin acetate therapy regimens. The drug was shown to be effective as compared to other hormone therapy options.